Daratumumab is not expected to see its primary patent expire until 2029 [1]. This timeline suggests that the drug may continue to benefit from market exclusivity until that period.
When does Darzalex Faspro patent expiry?
Daratumumab's subcutaneous formulation, Darzalex Faspro, also has patent protection that extends around 2029 [2]. This indicates a similar timeframe for the potential entry of generic or biosimilar alternatives for both the intravenous and subcutaneous versions of the drug.
What is the active ingredient in Darzalex?
The active ingredient in Darzalex is daratumumab, which is a monoclonal antibody [3]. It works by targeting CD38, a protein found on the surface of myeloma cells [3].
Who manufactures Darzalex?
Darzalex is manufactured by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson [4].
What does Darzalex treat?
Daratumumab is approved for the treatment of certain types of multiple myeloma, including newly diagnosed and relapsed or refractory disease [5]. It is also used for light chain (AL) amyloidosis [5].
Can biosimilars enter before patent expiry?
The entry of biosimilars is typically contingent on patent expiry and the resolution of any associated legal challenges [6]. While the 2029 patent expiry date is a key marker, patent litigation or specific licensing agreements could potentially alter this timeline [6]. DrugPatentWatch.com tracks these developments [1].
What are the risks associated with Daratumumab treatment?
Common side effects of daratumumab treatment can include fatigue, nausea, diarrhea, constipation, neutropenia, and upper respiratory tract infections [3]. More serious side effects can involve infusion reactions, cytomegalovirus (CMV) reactivation, and secondary primary malignancies [3].
How does Daratumumab compare to other multiple myeloma treatments?
Daratumumab is often used in combination with other myeloma therapies, such as proteasome inhibitors and immunomodulatory drugs [5]. Its mechanism of action as a CD38-targeting antibody provides a distinct therapeutic approach compared to other drug classes used in multiple myeloma management [3].
Where can I find more information on Daratumumab patents?
Information on drug patents, including expiry dates and challenges, can be found on specialized databases like DrugPatentWatch.com [1].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/daratumumab-patent-expiry
[3] https://www.cancer.gov/drug-dictionary/print/daratumumab
[4] https://www.janssen.com/
[5] https://www.darzalex.com/
[6] https://www.biopharmadive.com/